The Microsampling & Minimally Invasive Blood Collection Market 2026-2033 | Remote Diagnostics and Decentralized Trials Propel Market to $4.01 Billion by 2033

Dublin, Nov. 18, 2026 (GLOBE NEWSWIRE) -- "Microsampling & Minimally Invasive Blood Collection Market Size, Share & Trends Analysis Report by Product, Application, End Use, Region, and Growth Forecasts, 2026-2033" has been added to ResearchAndMarkets.com's offering.

The global microsampling & minimally invasive blood collection market is projected to reach USD 4.01 billion by 2033, up from USD 2.16 billion in 2025, expanding at a CAGR of 8.15% from 2026 to 2033. Market growth is being driven by the rising prevalence of chronic diseases, increasing demand for patient-centric diagnostics, technological innovation, and greater adoption of remote blood collection in decentralized clinical trials.

Blood-based analysis remains essential to clinical diagnostics, disease management, therapeutic monitoring, and medical research. Advances in molecular diagnostics now support reliable analysis using substantially smaller sample volumes, accelerating the transition from conventional centralized collection toward decentralized healthcare. Microsampling technologies improve access to testing, enhance patient convenience, and support remote care across home, clinical, and research environments.

The expanding burden of chronic disease is creating sustained demand for frequent and longitudinal diagnostic testing. According to the World Health Organization, chronic diseases caused approximately 43 million deaths in 2021, accounting for nearly 75% of non-pandemic-related deaths worldwide. This included 18 million premature deaths among people under 70. As healthcare providers seek scalable and cost-effective monitoring solutions, microsampling and minimally invasive blood collection technologies are gaining traction as alternatives to resource-intensive venous sampling.

Patient-centric care is another major market driver, particularly for people requiring regular testing, including chronic disease patients and pediatric and geriatric populations. Finger-stick collection, microneedle-based systems, self-collection devices, and remote blood collection kits support at-home testing and reduce dependence on conventional clinical facilities. Their adoption also aligns with the continued expansion of telehealth, mail-in diagnostics, and homecare services.

Technologies such as volumetric absorptive microsampling (VAMS), dried blood spot (DBS) collection, microfluidic systems, HemaPEN, and HemaXis are improving sample consistency, analyte stability, and analytical performance. These platforms address challenges related to sample volume, hematocrit variability, and sample homogeneity while supporting accurate and reproducible results. Dried matrix microsampling can also facilitate ambient-temperature transportation, reduce cold-chain requirements, lower storage needs, and simplify logistics.

Decentralized clinical trials represent a significant growth opportunity for the microsampling market. Remote self-collection allows participants to provide samples from home and ship them to centralized laboratories, reducing travel requirements and dependence on physical trial sites. This model can improve recruitment and retention, expand participation among geographically dispersed and underserved populations, shorten trial timelines, lower operational costs, and support broader patient representation. Serum microsampling devices, controlled shipping systems, and remote centrifugation capabilities further strengthen clinical and proteomic research applications.

Microsampling is also delivering ethical and operational benefits in preclinical research, particularly in toxicokinetic studies. Smaller sample volumes, composite sampling, and less invasive collection methods can reduce physiological stress and tissue damage in research animals. Serial sampling from the same animal may also reduce cohort requirements while maintaining data quality, supporting reduction and refinement principles as well as regulatory expectations.

Market Challenges

Despite a favorable growth outlook, market participants face increasing regulatory scrutiny and must demonstrate performance comparable to conventional testing methods. Advanced user-friendly devices may carry higher costs, creating adoption barriers in price-sensitive markets and regions with limited reimbursement. Strategic consolidation is also increasing as established companies acquire specialized innovators to expand product capabilities, technology portfolios, and geographic reach.

Report Segmentation

The report analyzes revenue growth and market opportunities at global, regional, and country levels from 2021 to 2033. Coverage includes the following segments:

  • Product: Microsampling devices, VAMS devices, push-button blood collection devices, microfluidic blood sampling devices, capillary blood collection devices, lancets, lancing devices, capillary tubes / microcollection tubes, microcollection containers, DBS cards, DBS collection kits, at-home blood collection devices, self-collection blood sampling devices, and remote blood collection kits.
  • Application: Disease diagnostics, therapeutic drug monitoring (TDM), clinical trials / decentralized clinical trials, neonatal & genetic screening, and health screening & preventive testing.
  • End-use: Hospitals & clinics, diagnostic laboratories, pharmaceutical & biotechnology companies / CROs, research & academic institutes, and homecare / self-testing.
  • Region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with country-level analysis across major established and emerging markets.

Key Benefits of the Report

  • Detailed market estimates, forecasts, growth drivers, and industry trend analysis.
  • Revenue assessment across product, application, end-use, regional, and country segments.
  • Competitive landscape analysis covering market presence, strategic positioning, and consolidation activity.
  • Evaluation of product innovation, remote sampling technologies, and emerging commercial opportunities.
  • Actionable market intelligence to support investment planning, competitive strategy, and revenue development.

The report provides decision-makers with a structured assessment of the technologies and market forces shaping microsampling, minimally invasive blood collection, remote diagnostics, therapeutic drug monitoring, and decentralized clinical research through 2033.

Key Attributes

Report Attribute Details
No. of Pages 120
Forecast Period 2025-2033
Estimated Market Value (USD) in 2025 $2.16 Billion
Forecasted Market Value (USD) by 2033 $4.01 Billion
Compound Annual Growth Rate 8.1%
Regions Covered Global


Companies Featured

  • BD
  • Abbott
  • F. Hoffmann-La Roche Ltd.
  • Terumo Corporation
  • PerkinElmer, Inc.
  • Neoteryx
  • Tasso Inc.
  • Seventh Sense Biosystems
  • Capitainer AB
  • Sarstedt AG & Co. KG

For more information about this report visit https://www.researchandmarkets.com/r/z1hrb3

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900